Pharmaceutical company Sotex was founded in 1999.
Sotex initially filled and packaged ready-made drugs under contracts with well-known western manufacturers: Nycomed, Lek, Pliva, Krka. This allowed the company to gain experience in production and quality control according to western standards.
Production of injectable forms launched. The Sotex plant became one of the first Russian enterprises built in full compliance with EU GMP requirements.
Sotex began licensed production of injectable drugs in partnership with foreign pharmaceutical manufacturers.
Sotex launched a line for production of genetically engineered drugs in pre-filled syringes.
Sotex started exports to neighboring and distant countries.
Acquisition of 100% of the business and assets of OJSC AnviLab allowed for a rapid growth of the product portfolio in the OTC segment.
A dedicated production area was launched to produce genetically-engineered substance erythropoietin – the API in Eralfon® ready formulation.
A thirdampoule production line was launched, which allowed Sotex to double its injectable formulations production capacities.
Sotex ampoule production received an EU GMP certificate.
PROTEK Group finalized acquisition of Rafarma.